Mesenchymal stem cells: immune evasive, not immune privileged

By J. Ankrum, Joon Faii Ong, J. Karp. Nature Biotechnology, 2014

1,399 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Surgery

View Paper: https://www.semanticscholar.org/paper/19d5d5e94ed9771f36798537735d2c2efdb31f73

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Lorraine O'Driscoll
2. P. Vader
3. B. W. van Balkom

In Surgery

1. Lorraine O'Driscoll

Citations in the corpus

• Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs (2019, background): “Allogeneic MSCs are frequently used in clinical studies even though their immunogenic potential has not always been taken into account (88).”
• Challenges and advances in clinical applications of mesenchymal stromal cells (2021, background): “Generally, the original MSCs are believed to have low immunogenicity [16].”
• Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper (2015, background): “MSCs may be rejected by the host’s immune system, and a discussion has begun about the efficacy of allo-MSC transplantation (285).”
• Mesenchymal stromal cells: clinical challenges and therapeutic opportunities (2018, background): “Indeed, the notion of MSC being immunoevasive and not immune privileged has been proposed(Ankrum et al., 2014).”